Nonalcoholic Steatohepatitis (NASH) Latest Advances

Hepatoprotection of Jianpi Qingre Lishi prescription on non-alcoholic steatohepatitis miRNA-27/peroxisome proliferator-activated receptor gamma axis.

Journal: Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan

Published: June 28, 2026

Corrigendum to "Pharmaceutical optimization of chitosan tablets is associated with reduced circulating bile acids and fibrosis-related molecular signatures in non-alcoholic steatohepatitis rats" [Carbohydrate Polymers 383 (2026) 125333].

Journal: Carbohydrate polymers

Published: June 02, 2026

Correction: Empagliflozin attenuates dexamethasone-induced non-alcoholic steatohepatitis by regulation of ferroptosis, inflammation and autophagy.

Journal: Frontiers in pharmacology

Published: May 07, 2026

Corrigendum to "CISD2-mediated mitochondrial dysfunction and iron redistribution contributes to ferroptosis in arsenic-induced nonalcoholic steatohepatitis" [Ecotoxicol. Environ. Saf. 289:117694/EES-23-4255].

Journal: Ecotoxicology and environmental safety

Published: April 15, 2026

Comment on "Unveiling Resmetirom: A Systematic Review and Meta-Analysis on Its Impact on Liver Function and Safety in Non-Alcoholic Steatohepatitis Treatment".

Journal: JGH open : an open access journal of gastroenterology and hepatology

Published: April 06, 2026

Editorial: Adaptive immune regulation of non-alcoholic steatohepatitis (NASH).

Journal: Frontiers in immunology

Published: April 02, 2026

Arsenic Promotes Nonalcoholic Steatohepatitis via MCFD2-Induced PERK/eIF2α-Mediated Integrated Stress Response.

Journal: Chemico-biological interactions

Published: March 29, 2026

Correction: Empagliflozin attenuates dexamethasone-induced non-alcoholic steatohepatitis by regulation of ferroptosis, inflammation and autophagy.

Journal: Frontiers in pharmacology

Published: March 20, 2026

Effects of Zaozhu Yinchen Decoction on a Rat Model of Nonalcoholic Steatohepatitis via Regulation of Myeloid-Derived Suppressor Cells.

Journal: Hepatic medicine : evidence and research

Published: March 07, 2026

Correction to "Design, Synthesis, and Biological Evaluation of Chromone Derivatives as STAT1 Inhibitors for Treatment of Nonalcoholic Steatohepatitis".

Journal: Journal of medicinal chemistry

Published: March 05, 2026

MRI multicomponent relaxometry for liver fibrosis, inflammation, and steatosis in nonalcoholic steatohepatitis: A prospective study.

Journal: European journal of radiology

Published: March 04, 2026

Pharmaceutical optimization of chitosan tablets is associated with reduced circulating bile acids and fibrosis-related molecular signatures in non-alcoholic steatohepatitis rats.

Journal: Carbohydrate polymers

Published: January 30, 2026

Nonalcoholic Steatohepatitis (NASH) Latest Advances

Find the Latest Research About Nonalcoholic Steatohepatitis (NASH)

Hepatoprotection of Jianpi Qingre Lishi prescription on non-alcoholic steatohepatitis miRNA-27/peroxisome proliferator-activated receptor gamma axis.

Hepatoprotection of Jianpi Qingre Lishi prescription on non-alcoholic steatohepatitis miRNA-27/peroxisome proliferator-activated receptor gamma axis.

Corrigendum to "Pharmaceutical optimization of chitosan tablets is associated with reduced circulating bile acids and fibrosis-related molecular signatures in non-alcoholic steatohepatitis rats" [Carbohydrate Polymers 383 (2026) 125333].

Corrigendum to "Pharmaceutical optimization of chitosan tablets is associated with reduced circulating bile acids and fibrosis-related molecular signatures in non-alcoholic steatohepatitis rats" [Carbohydrate Polymers 383 (2026) 125333].

Correction: Empagliflozin attenuates dexamethasone-induced non-alcoholic steatohepatitis by regulation of ferroptosis, inflammation and autophagy.

Correction: Empagliflozin attenuates dexamethasone-induced non-alcoholic steatohepatitis by regulation of ferroptosis, inflammation and autophagy.

Corrigendum to "CISD2-mediated mitochondrial dysfunction and iron redistribution contributes to ferroptosis in arsenic-induced nonalcoholic steatohepatitis" [Ecotoxicol. Environ. Saf. 289:117694/EES-23-4255].

Corrigendum to "CISD2-mediated mitochondrial dysfunction and iron redistribution contributes to ferroptosis in arsenic-induced nonalcoholic steatohepatitis" [Ecotoxicol. Environ. Saf. 289:117694/EES-23-4255].

Comment on "Unveiling Resmetirom: A Systematic Review and Meta-Analysis on Its Impact on Liver Function and Safety in Non-Alcoholic Steatohepatitis Treatment".

Comment on "Unveiling Resmetirom: A Systematic Review and Meta-Analysis on Its Impact on Liver Function and Safety in Non-Alcoholic Steatohepatitis Treatment".

Editorial: Adaptive immune regulation of non-alcoholic steatohepatitis (NASH).

Editorial: Adaptive immune regulation of non-alcoholic steatohepatitis (NASH).

Arsenic Promotes Nonalcoholic Steatohepatitis via MCFD2-Induced PERK/eIF2α-Mediated Integrated Stress Response.

Arsenic Promotes Nonalcoholic Steatohepatitis via MCFD2-Induced PERK/eIF2α-Mediated Integrated Stress Response.

Correction: Empagliflozin attenuates dexamethasone-induced non-alcoholic steatohepatitis by regulation of ferroptosis, inflammation and autophagy.

Correction: Empagliflozin attenuates dexamethasone-induced non-alcoholic steatohepatitis by regulation of ferroptosis, inflammation and autophagy.

Effects of Zaozhu Yinchen Decoction on a Rat Model of Nonalcoholic Steatohepatitis via Regulation of Myeloid-Derived Suppressor Cells.

Effects of Zaozhu Yinchen Decoction on a Rat Model of Nonalcoholic Steatohepatitis via Regulation of Myeloid-Derived Suppressor Cells.

Correction to "Design, Synthesis, and Biological Evaluation of Chromone Derivatives as STAT1 Inhibitors for Treatment of Nonalcoholic Steatohepatitis".

Correction to "Design, Synthesis, and Biological Evaluation of Chromone Derivatives as STAT1 Inhibitors for Treatment of Nonalcoholic Steatohepatitis".

MRI multicomponent relaxometry for liver fibrosis, inflammation, and steatosis in nonalcoholic steatohepatitis: A prospective study.

MRI multicomponent relaxometry for liver fibrosis, inflammation, and steatosis in nonalcoholic steatohepatitis: A prospective study.

Pharmaceutical optimization of chitosan tablets is associated with reduced circulating bile acids and fibrosis-related molecular signatures in non-alcoholic steatohepatitis rats.

Pharmaceutical optimization of chitosan tablets is associated with reduced circulating bile acids and fibrosis-related molecular signatures in non-alcoholic steatohepatitis rats.